About the Open Letter

The Open Letter to the Food and Drug Administration is a harm reduction and research advocacy initiative in partnership with Hystelica, a research organization dedicated to understanding safe and effective psychedelic use for women. The letter intends to address the urgent need for psychedelic research on female biology, including the effect of stages of the menstrual cycle as mentioned in the FDA’s Evaluation of Gender Differences in Clinical Investigations.